The COVID crisis will spur leaders of life sciences companies around the world to focus on longstanding pain points that AI could help alleviate. And the execs are looking to put their money where their responses are.

When it comes to predicting an individual’s risk of suffering a heart attack or stroke over the next 10 years, machine learning models are no more consistent than traditional statistical techniques.

Along with AI, this ongoing list includes regulatory clearances of virtual and augmented reality, 3D printing and other emerging technologies targeted for healthcare.

Leaders of the venture, dubbed “Project Amber,” are open-sourcing their technology and findings in the hope that other mental health researchers can take things from here.

A university, health system and tech giant are piloting the use of deep learning with IoT and edge computing to block COVID-19 from infiltrating a 548-bed hospital.

A new AI tool can accurately separate the patients who would do better getting restorative sleep till morning from those who, due to unstable condition, really need their vital signs checked overnight.

The COVID crisis has given AI a chance to shine for medical researchers this year—and shine it has, judging by one prominent center’s experience.

The temporary telehealth reforms put in place to help the U.S. weather the COVID-19 storm “are good for patients and should be made permanent.”

Will the public be braced enough for the expected side effects of shot No. 1 that they’ll follow through with the essential second round?

President-elect Joe Biden wants to drop Medicare’s eligibility age to 60. If he succeeds, the move might bring in well more than 20 million new enrollees. What are the odds he’ll plant that piece of a potentially sweeping healthcare agenda?